Trial Profile
Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 18 Feb 2021 Results published in the Clinical Cancer Research